View in EDS

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.

Saved in:
Bibliographic Details
Title: Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
Authors: Jebbink M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boelens MC; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Department of Statistics, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Gooijer CJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mahn M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Wekken AJ; Department of Pulmonology, University of Groningen and University of Medical Centre Groningen, Groningen, The Netherlands., Hendriks L; Department of Pulmonology, MUMC, Maastricht, The Netherlands.; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Hashemi SMS; Department of Pulmonary Medicine, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Paats MS; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dingemans AC; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2023 Feb 24; Vol. 4 (4), pp. 100481. Date of Electronic Publication: 2023 Feb 24 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37035409
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jebbink+M%22">Jebbink M</searchLink>; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Langen+AJ%22">de Langen AJ</searchLink>; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Monkhorst+K%22">Monkhorst K</searchLink>; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Boelens+MC%22">Boelens MC</searchLink>; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Broek+D%22">van den Broek D</searchLink>; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Noort+V%22">van der Noort V</searchLink>; Department of Statistics, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Gooijer+CJ%22">de Gooijer CJ</searchLink>; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mahn+M%22">Mahn M</searchLink>; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Wekken+AJ%22">van der Wekken AJ</searchLink>; Department of Pulmonology, University of Groningen and University of Medical Centre Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hendriks+L%22">Hendriks L</searchLink>; Department of Pulmonology, MUMC, Maastricht, The Netherlands.; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hashemi+SMS%22">Hashemi SMS</searchLink>; Department of Pulmonary Medicine, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Paats+MS%22">Paats MS</searchLink>; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dingemans+AC%22">Dingemans AC</searchLink>; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Smit+EF%22">Smit EF</searchLink>; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2023 Feb 24; Vol. 4 (4), pp. 100481. <i>Date of Electronic Publication: </i>2023 Feb 24 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37035409
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2023.100481
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100481
    Titles:
      – TitleFull: Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jebbink M
      – PersonEntity:
          Name:
            NameFull: de Langen AJ
      – PersonEntity:
          Name:
            NameFull: Monkhorst K
      – PersonEntity:
          Name:
            NameFull: Boelens MC
      – PersonEntity:
          Name:
            NameFull: van den Broek D
      – PersonEntity:
          Name:
            NameFull: van der Noort V
      – PersonEntity:
          Name:
            NameFull: de Gooijer CJ
      – PersonEntity:
          Name:
            NameFull: Mahn M
      – PersonEntity:
          Name:
            NameFull: van der Wekken AJ
      – PersonEntity:
          Name:
            NameFull: Hendriks L
      – PersonEntity:
          Name:
            NameFull: Hashemi SMS
      – PersonEntity:
          Name:
            NameFull: Paats MS
      – PersonEntity:
          Name:
            NameFull: Dingemans AC
      – PersonEntity:
          Name:
            NameFull: Smit EF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 02
              Text: 2023 Feb 24
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3643
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: JTO clinical and research reports
              Type: main
ResultId 1